SEARCH

SEARCH BY CITATION

References

  • Armstrong, M.B., Schumacher, K.R., Mody, R., Yanik, G.A., Opipari, A.W. Jr & Castle, V.P. (2008) Bortezomib as a therapeutic candidate for neuroblastoma. Journal of Experimental Therapeutics and Oncology, 7, 135145.
  • Balleari, E., Ghio, R., Falcone, A. & Musto, P. (2004) Possible multiple myeloma dedifferentiation following thalidomide therapy: a report of four cases. Leukaemia and Lymphoma, 45, 735738.
  • Blade, J., Fernandez de Larrea, C., Rosinol, L., Cibeira, M.T., Jimenez, R. & Powles, R. (2011) Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. Journal of Clinical Oncology, 29, 38053812.
  • Dawson, M.A., Patil, S. & Spencer, A. (2007) Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica, 92, 143144.
  • Demo, S.D., Kirk, C.J., Aujay, M.A., Buchholz, T.J., Dajee, M., Ho, M.N., Jiang, J., Laidig, G.J., Lewis, E.R., Parlati, F., Shenk, K.D., Smyth, M.S., Sun, C.M., Vallone, M.K., Woo, T.M., Molineaux, C.J. & Bennett, M.K. (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Research, 67, 63836391.
  • Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 14671473.
  • Fassas, A.B., Muwalla, F., Berryman, T., Benramdane, R., Joseph, L., Anaissie, E., Sethi, R., Desikan, R., Siegel, D., Badros, A., Toor, A., Zangari, M., Morris, C., Angtuaco, E., Mathew, S., Wilson, C., Hough, A., Harik, S., Barlogie, B. & Tricot, G. (2002) Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. British Journal of Haematology, 117, 103108.
  • Hattori, Y. & Iguchi, T. (2004) Thalidomide for the treatment of multiple myeloma. Congenit Anom (Kyoto), 44, 125136.
  • Hemeryck, A., Geerts, R., Monbaliu, J., Hassler, S., Verhaeghe, T., Diels, L., Verluyten, W., van Beijsterveldt, L., Mamidi, R.N., Janssen, C. & De Coster, R. (2007) Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib. Cancer Chemotherapy and Pharmacology, 60, 777787.
  • Koschny, R., Holland, H., Sykora, J., Haas, T.L., Sprick, M.R., Ganten, T.M., Krupp, W., Bauer, M., Ahnert, P., Meixensberger, J. & Walczak, H. (2007) Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clinical Cancer Research, 13, 34033412.
  • Kuhnemund, A., Liebisch, P., Bauchmuller, K., zur Hausen, A., Veelken, H., Wasch, R. & Engelhardt, M. (2009) ‘Light-chain escape-multiple myeloma’-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. Journal of Cancer Research and Clinical Oncology, 135, 477484.
  • Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. & Gertz, M.A. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 25162520.
  • Mele, G., Pinna, S., Alloro, E., Brocca, M.C., Coppi, M.R. & Quarta, G. (2007) Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma. Leukemia Research, 31, 721723.
  • Muscal, J.A., Sun, Y., Nuchtern, J.G., Dauser, R.C., McGuffey, L.H., Gibson, B.W. & Berg, S.L. (2012) Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemotherapy and Pharmacology, 69, 943947.
  • Mussetti, A., Dalto, S. & Montefusco, V. (2013) Effective treatment of pomalidomide in central nervous system myelomatosis. Leukaemia and Lymphoma, 54, 864866.
  • Nieuwenhuizen, L. & Biesma, D.H. (2008) Central nervous system myelomatosis: review of the literature. European Journal of Haematology, 80, 19.
  • Petersen, S.L., Wagner, A. & Gimsing, P. (1999) Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature. American Journal of Hematology, 62, 228233.
  • Richardson, P.G., Spencer, A., Cannell, P., Harrison, S.J., Catley, L., Underhill, C., Zimmerman, T.M., Hofmeister, C.C., Jakubowiak, A.J., Laubach, J.P., Palladino, M.A., Longenecker, A.M., Lay, A., Wear, S., Lloyd, G.K., Hannah, A.L., Reich, S., Spear, M.A. & Anderson, K.C. (2011) Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 118, 302.
  • Rudick, R.A., Peter, D.R., Bidlack, J.M. & Knutson, D.W. (1985) Multiple sclerosis: free light chains in cerebrospinal fluid. Neurology, 35, 14431449.
  • Schwartz, R. & Davidson, T. (2004) Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park), 18, 1421.
  • Short, K.D., Rajkumar, S.V., Larson, D., Buadi, F., Hayman, S., Dispenzieri, A., Gertz, M., Kumar, S., Mikhael, J., Roy, V., Kyle, R.A. & Lacy, M.Q. (2011) Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia, 25, 906908.
  • Varettoni, M., Corso, A., Pica, G., Mangiacavalli, S., Pascutto, C. & Lazzarino, M. (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Annals of Oncology, 21, 325330.